Photo taken from: Jason Westin/LinkedIn
Dec 18, 2023, 23:45
Jason Westin: Targeted therapy combinations are safe and effective as an initial treatment for patients with Large B-cell Lymphoma
Jason Westin, Director of Clinical Research and Section Chief of Aggressive Lymphoma at MD Anderson Cancer Centre, shared the following on LinkedIn:
“I was honored to present our investigator initiated trial at the 2023 ASH Annual meeting. We showed that targeted therapy combinations are safe and effective as an initial treatment for patients with Large B-cell Lymphoma, and may allow for reducing or removing the need for chemotherapy. LTRA (lenalidomide, tafasitamab, rituximab, and acalabrutinib) had a complete response rate of 63% prior to chemotherapy, and 100% at end of treatment with our response adapted approach. Progress!”
For details click here.
Source: Jason Westin/LinkedIn
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 18, 2025, 09:21